NVAX
Novavax IncNASDAQ
Healthcare • Biotechnology
Updated 1 day ago
Coverage limited
Factor tilt: Anti-Value Mid Cap
$12.82+1.26%
Close Oct 13, 2026
- Market cap
- $2.11B
- 1 month
- +33.7%
- 3 months
- +52.1%
- 1 year
- +53.9%
- 52-week range
- $6.22$12.82
- Dividend
- No payments on record
- Next-quarter EPS estimate
- -$0.18Quarter to Sep 30, 2026 · 8 analysts · revenue $84.75M
- Short interest
- 32.3% of float46M shares · settled Sep 30, 2026 · -7.7% since Sep 15, 2026 · FINRA
Fundamentals · trailing 12 months to Jun 30, 2026
- Revenue
- $413.8M
- Net income
- -$247.73M
- Free cash flow
- -$43.59M
- Book value
- —
- Total debt
- $295.6M
- P/E
- —
- Price / sales
- 5.1×
- Price / book
- —
- FCF yield
- -2.1%
- Net margin
- -59.9%
EODHD (TTM) · as of Oct 13, 2026
End-of-day close from stored market data, not a live quote.
Portfolio context
Sign in to see your position size
We’ll show you if NVAX is in your portfolio and how much it contributes.
Sign inMarket context
Loading market dates
No upcoming ex-dividend date announced
No 8-K filings in the last 30 days.
Smart money context
Holder IQ: MEDIUM
30 top institutions tracked
as of 2026-Q2 (filed 2026-09-22)
Last 13F trend: accumulating (heavy)
Unlock crowding heatmapUnlock filer discoveryInsider context
Sentiment: unknown
No recent insider trades detected.
Red flags: 6
Largest 13-F holders · Q2 2026
267 filers reported a long position in NVAX for Q2 2026. 13-F holdings are filed up to 45 days after the quarter ends.
| Holder | Value | Shares | Shares vs Q1 2026 |
|---|---|---|---|
| SHAH CAPITAL MANAGEMENT | $133.4M | 14.2M | -4.6% |
| BlackRock, Inc. | $131.4M | 13.9M | +8.6% |
| STATE STREET CORP | $110.6M | 11.7M | +30.9% |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $71.7M | 7.6M | +6.4% |
| VANGUARD CAPITAL MANAGEMENT LLC | $68.4M | 7.3M | +1.8% |
| Sanofi | $64.8M | 6.9M | Unchanged |
| D. E. Shaw & Co., Inc. | $53.2M | 5.7M | -26.7% |
| GEODE CAPITAL MANAGEMENT, LLC | $39.6M | 4.2M | +7.9% |
| TWO SIGMA INVESTMENTS, LP | $38.5M | 4.1M | +565.4% |
| COATUE MANAGEMENT LLC | $36.1M | 3.8M | Unchanged |
Get the Full Analysis for NVAX
Unlock detailed insider transactions, institutional holder changes, factor exposures, and personalized alerts. Start free with your own portfolio.